This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS : Primary study objective: Rate of 6-month progression-free survival (PFS) at doses of 500 mg or 2000 mg administered twice a week during a 4-week cycle. Secondary objectives: To estimate response rate; survival time; rate of 1-year survival; time to disease progression; safety and tolerability; quality of life and pharmacokinetics (PK).
Showing the most recent 10 out of 1085 publications